The Outpatient Shift: Private Equity's Play in Prostate Care

VOORHEES, N.J. – October 20, 2026 — The landscape of American healthcare is being redrawn, not just in the halls of Congress or the laboratories of pharmaceutical giants, but in the unassuming suburban office parks of places like Monroe and Voorhees, New Jersey. The recent announcement that New Jersey Urology is opening two advanced outpatient interventional radiology centers is more than a local business expansion. It is a prime case study in the broader systemic forces reshaping how we experience medical care—specifically, the collision of minimally invasive medical technology and private equity investment.

Affiliated with U.S. Urology Partners—a management services organization backed by the private equity powerhouse General Atlantic—New Jersey Urology is expanding its footprint to offer image-guided treatments outside the traditional hospital setting. The new centers, developed in partnership with IR Centers and Prostate Centers USA, will be led by three nationally recognized interventional radiologists: Dr. Arun Chockalingam, Dr. Gregg Khodorov, and Dr. Haokang Wei.

On the surface, this is a story about clinical innovation and patient convenience. But look deeper, and it reveals a fundamental shift in the business of healthcare: the migration of lucrative, specialized procedures away from acute-care hospitals and into privately owned, community-based ambulatory facilities.

Moving the Operating Room to the Suburbs

For decades, men suffering from benign prostatic hyperplasia—an enlarged prostate causing severe lower urinary tract symptoms—faced a daunting standard of care. The conventional surgical approach, transurethral resection of the prostate, commonly known as TURP, typically requires general anesthesia, an overnight hospital stay, and a painful recovery period involving catheterization. It also carries significant risks of side effects, including bleeding and sexual dysfunction.

The new facilities in Middlesex and Camden counties are designed to offer an alternative: prostate artery embolization. PAE is a minimally invasive procedure that blocks the blood vessels supplying the prostate, causing the gland to shrink. The clinical data supporting PAE is compelling. Studies show that 70 to 90 percent of men experience significant, sustained symptom improvement. The procedure is performed on an outpatient basis, allowing patients to recover at home the same day.

The medical establishment has taken note. The American Urological Association recently elevated PAE to Grade B evidence in its 2026 guidelines, while the Society of Interventional Radiology has consistently championed the procedure as a safe, effective alternative to conventional surgery for patients who cannot tolerate surgery or wish to preserve sexual function.

“The opening of these interventional radiology centers represents an important step in the continued evolution of New Jersey Urology,” stated Dr. Gordon A. Brown, President of New Jersey Urology, in the company’s press release. “Our goal is to provide patients with access to the most advanced and effective treatment options available, while delivering care in the setting that is most convenient for them.”

By shifting care from the operating room to the outpatient clinic, patients benefit from reduced reliance on hospital-based care and faster recoveries. But this clinical migration is also inextricably linked to a sophisticated financial strategy.

The Financial Engine Behind the Clinic

To understand the proliferation of centers like those in Monroe and Voorhees, one must look at the financial architecture supporting them. New Jersey Urology’s parent organization, U.S. Urology Partners, operates a network of more than 70 locations across seven states. It is fueled by capital from General Atlantic, reflecting a massive trend of private equity investment in specialty ambulatory centers.

Private equity firms are drawn to specialty practices for several reasons. The market is highly fragmented, making it ripe for consolidation. An aging population provides a steady, growing demand for services like urology. But the real margin expansion comes from integrating ancillary services. By bringing interventional radiology in-house, a urology practice captures a larger portion of the patient care continuum. Instead of referring a patient to an independent hospital for an embolization or complex imaging, the practice retains that revenue stream within its own network.

This model creates a highly efficient, integrated treatment pathway. Dr. Chidebelu Ufodike, Chief Operating Officer of New Jersey Urology, noted this operational advantage: “This launch reflects how we want to continue growing at New Jersey Urology, bringing advanced services closer to our patients while making their care journey as seamless as possible. By integrating interventional radiology directly into our clinical network, we can better coordinate referral, consultation, treatment and follow-up.”

However, the private equity playbook in healthcare is not without its critics. While capital injections can fund state-of-the-art technology and streamline administrative burdens, the imperative to deliver high returns to investors can fundamentally alter practice dynamics. The focus on efficiency and volume can sometimes pressure staffing levels and patient access. Yet, in the case of outpatient PAE, the financial incentives appear to align with payer preferences, as the procedure generally carries lower mean total costs than traditional inpatient surgery, satisfying both the investors' need for efficiency and the insurers' desire for cost containment.

Bridging the Specialty Divide

Perhaps the most fascinating aspect of this expansion is the collaboration it requires. Historically, urologists and interventional radiologists have operated in separate silos, sometimes even competing for the same patient populations. Urologists are surgeons by training, traditionally favoring procedures like TURP. Interventional radiologists are image-guidance specialists who pioneered embolization techniques.

When a patient presented with an enlarged prostate, the treatment they received often depended on which specialist they saw first. The joint venture between New Jersey Urology, IR Centers, and Prostate Centers USA represents a strategic truce. By integrating these specialties under one corporate umbrella, the practice aligns referral streams rather than maintaining traditional rivalries.

“When you bring competing specialties into a shared financial and clinical model, you eliminate the turf war,” noted one healthcare strategy analyst familiar with regional market dynamics. “The urologist no longer loses a patient by recommending an embolization; instead, the patient stays within the network, receiving the most appropriate care without the friction of out-of-network referrals.”

This collaborative care model extends beyond prostate issues. The new centers will also offer advanced embolization therapies for chronic pelvic pain, hemorrhoidal disease, and musculoskeletal conditions, further diversifying the clinical offerings and revenue potential of the outpatient clinics.

The Ripple Effect on Regional Health Systems

As private-equity-backed specialty groups successfully siphon lucrative, elective procedures out of the hospital setting, traditional health systems are feeling the strain. The opening of these centers in Monroe and Voorhees places New Jersey Urology in direct competition with major regional hospital networks.

In Camden County, systems like Virtua Health have long relied on their urology and interventional radiology departments to drive surgical volumes. In Middlesex County, heavyweights like Hackensack Meridian Health and RWJBarnabas Health face similar pressures. When a community-based practice offers a faster, less invasive, and potentially cheaper alternative in a convenient suburban strip mall, hospitals inevitably see a decline in their own elective surgical cases.

This dynamic forces hospitals to adapt. As routine procedures like PAE migrate to outpatient centers, hospitals are left to manage the most complex, high-acuity cases—patients who require intensive care, have significant comorbidities, or are suffering from emergencies. This shifting case mix can squeeze hospital margins, prompting them to either aggressively expand their own outpatient footprints or double down on highly specialized inpatient care.

Ultimately, the expansion of New Jersey Urology is a microcosm of the modern American healthcare system at work. It is a landscape where clinical innovation is accelerated by private capital, where patient convenience is packaged as a competitive advantage, and where the traditional hospital is no longer the undisputed center of medical care. For the patients walking through the doors in Monroe and Voorhees, the result is a less invasive path to recovery. For the healthcare industry at large, it is yet another signal that the future of medicine is moving rapidly into the outpatient arena.